Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) CEO Sean Bohen Sells 52,328 Shares

by · The Markets Daily

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) CEO Sean Bohen sold 52,328 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $9.37, for a total value of $490,313.36. Following the sale, the chief executive officer now owns 298,836 shares in the company, valued at approximately $2,800,093.32. This trade represents a 14.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Olema Pharmaceuticals Trading Down 12.8 %

Shares of Olema Pharmaceuticals stock traded down $1.23 during midday trading on Wednesday, reaching $8.41. The company had a trading volume of 2,119,334 shares, compared to its average volume of 740,302. The stock has a fifty day simple moving average of $10.97 and a 200 day simple moving average of $11.94. Olema Pharmaceuticals, Inc. has a 1-year low of $7.68 and a 1-year high of $16.77. The company has a market capitalization of $481.88 million, a price-to-earnings ratio of -4.05 and a beta of 1.92.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Olema Pharmaceuticals in a report on Wednesday. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $27.00.

Read Our Latest Research Report on OLMA

Institutional Investors Weigh In On Olema Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Conway Capital Management Inc. bought a new position in Olema Pharmaceuticals in the third quarter valued at about $119,000. China Universal Asset Management Co. Ltd. lifted its position in Olema Pharmaceuticals by 67.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,014 shares of the company’s stock valued at $132,000 after purchasing an additional 4,442 shares during the period. Portland Investment Counsel Inc. bought a new position in shares of Olema Pharmaceuticals in the 3rd quarter valued at about $143,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Olema Pharmaceuticals during the 2nd quarter worth approximately $145,000. Finally, SG Americas Securities LLC bought a new stake in shares of Olema Pharmaceuticals during the third quarter worth approximately $156,000. 91.78% of the stock is owned by institutional investors and hedge funds.

Olema Pharmaceuticals Company Profile

(Get Free Report)

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.

See Also